Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 3/20 | 0.54 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.54 |
| ▸ | FABP3 | P05413 | 5/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.55 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.55 |
| ▸ | TERT | O14746 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL7117179 | 0.98 | FABP3 (0.58) | FABP3LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL4817492 | 0.92 | FABP3 (0.56) | FABP3LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL3917799 | 0.90 | DGKA (0.53) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL28261297 | 0.90 | DGKA (0.53) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL28896537 | 0.90 | DGKA (0.53) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| Zinc Ion SCHEMBL28659701 | 0.88 | DGKA (0.52) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL28616840 | 0.88 | DGKA (0.52) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL28353538 | 0.88 | DGKA (0.52) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL8975164 | 0.88 | DGKA (0.52) | LPAR1LPAR4LPAR2LPAR3MAPT | |
| SCHEMBL29089011 | 0.88 | DGKA (0.52) | LPAR1LPAR4LPAR2LPAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-02-13 | — | — | US | claimed |
| US-20240382504-A1 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-11-21 | — | — | US | claimed |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | claimed |
| EP-4277951-A1 | PHENOL FORMALDEHYDE RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2023-11-22 | — | — | EP | claimed |
| EP-4277952-A1 | AMINOPLAST RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2023-11-22 | — | — | EP | claimed |
| WO-2022152946-A1 | PHENOL FORMALDEHYDE RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2022-07-21 | — | — | WO | claimed |
| WO-2022152901-A1 | AMINOPLAST RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2022-07-21 | — | — | WO | claimed |
| US-20190099342-A1 | COOLING PRODUCT | SYMRISE AG (DE) | 2019-04-04 | — | — | US | claimed |
| US-5858266-A | CONTAINING A HYDROFLUOROCARBON, A PHOSPHOROUS COMPOUND AND AN OXYGEN-CONTAINING ORGANIC COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 1999-01-12 | — | — | US | claimed |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-1469051-A1 | Shoe and leather care product | Sara Lee/DE N.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| US-6642194-B2 | Clear hair shampoo composition comprising detersive component, emulsifier component and polysiloxane component in amount effective as hair conditioner | CHEMSIL SILICONES, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6605577-B1 | Having a hindered amine group; hair shampoo | CHEMSIL SILICONES, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030134760-A1 | Clear conditioning detersive compositions and methods for making the same | CHEMSIL SILICONES, INC. | 2003-07-17 | — | — | US | disclosed |
| US-5858266-A | CONTAINING A HYDROFLUOROCARBON, A PHOSPHOROUS COMPOUND AND AN OXYGEN-CONTAINING ORGANIC COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382504-A1 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | CUTA, LIPA, CETP | PPARG 544/4885ADORA3 2516/4885PTGS1 1496/4885 |
| US-20190099342-A1 | COOLING PRODUCT | TRPA1, TRPV2, NISCH | PPARG 487/4885ADORA3 2852/4885PTGS1 584/4885 |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | PDE12, PDE4A, SMPD4 | PPARG 2064/4885ADORA3 2845/4885PTGS1 1153/4885 |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | PPARG 2064/4885ADORA3 2845/4885PTGS1 1153/4885 |
| US-20030134760-A1 | Clear conditioning detersive compositions and methods for making the same | ASH2L, CD47, THOC2 | PPARG 1114/4885ADORA3 2792/4885PTGS1 2176/4885 |
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | PPARG 2064/4885ADORA3 2845/4885PTGS1 1153/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | PPARG 697/4885ADORA3 525/4885PTGS1 3/4885 |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, SMPD4, PDE4A | PPARG 1703/4885ADORA3 2059/4885PTGS1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.